Lacril is a drug in the form of a 1% solution of high-molecular fractions of sodium hyaluronate of the maximum degree of purification for injections aimed at the treatment of diseases of the musculoskeletal system of non-infectious etiology in sports horses, dogs and cats. It is presented in disposable syringes of a special design for professional use.
Injecting Lacryl into a joint increases the volume and viscosity of the synovial fluid, thereby reducing pain and increasing joint mobility. The use of Lacryl at the initial stages of the development of pathology increases the effectiveness of the treatment of the joint. A single injection of Lacryl can significantly improve the functioning of the joint and relieve pain (especially in the early stages of arthrosis).
In the course of production of a preparation animal proteins are not used that practically excludes a possibility of emergence of allergic reactions. The drug is a sterile, hypoallergenic, non-toxic, non-pyrogenic natural biopolymer. It has high elasticity and well-defined viscosity (similar to those of the synovial fluid of an animal), is characterized by thermal stability, the absence of protein waste, and a high safety profile.
The drug has no analogues.
For intraarticular, periarticular and intravenous (according to indications) administration.
Indications for use:
Treatment of acute and chronic arthrosis, polyarthrosis, arthrosis-arthritis, osteoarthritis, subacute and chronic arthritis, acute and chronic synovitis, tendovaginitis, tendinosis, bursitis and osteochondrosis of non-infectious etiology, postoperative lavage, postoperative period.
Packing: 1 syringe x 2 ml. in sterile packaging.
Lacryl is not doping and does not contain substances prohibited by the rules of the Jockey Club and the FEI.